Back to Cancer Australia's website

Cancer Australia

Select a guideline

Recommendations for use of Taxane-containing chemotherapy regimens

Details of trials or studies

Table 1: Details of the adjuvant trials included in the Cochrane meta-analysis2
TRIAL PATIENT NUMBERS INTERVENTION COMPARATOR
CALGB 93444 3121 AC x 4 P x 4 AC x 4
Jones5 1016 DC x 4 AC x 4
BCIRG 0016 1491 DAC x 6 FAC x 6
E21977 2889 AD x 4 AC x 4
ECTO8 904 AP x 4 CMF x 4 A x 4 CMF x 4
GEICAM 99069 1248 FEC90 x 4 P x 8 FEC90 x 6
HECOG10 595 E x 4 P x 3 CMF x 4 E x 4 CMF x 4
NSABP B-2811 3059 AC x 4 P x 4 AC x 4
FinHer12 1010 D x 3 (+/- T) FEC60 x 3 Vin x 3 (+/- T) FEC60 x 3
PACS 0113 1999 FEC100 x 3 D x 3 FEC100 x 6
Taxit 21614 972 E x 4 D x 4 CMF x 4 E x 4 CMF x 3
BIG 2-9815 2887 A x 3 D x 3 CMF x 3AD x 4 CMF x 4 A x 4 CMF x 3 AC x 4 CMF x 3

Notes: A=doxorubicin; C=cyclophosphamide; D=docetaxel; E=epirubicin; F=flurouracil; M=methotrexate; P=paclitaxel; T=trastuzumab; Vin=vinorelbine

Table 2. Overall and disease-free survival sub-group analyses
SUB-GROUP ANALYSIS** OVERALL SURVIVAL OR (95% CI) DISEASE-FREESURVIVAL OR (95% CI)
Overall effect of taxanes 0.81 (0.75-0.88), p<0.00001 0.81 (0.77-0.86), pd0.00001
Type of taxane
Docetaxel 0.76 (0.67-0.86), p<0.0001 0.80 (0.74-0.87), pd0.00001
Paclitaxel 0.85 (0.76-0.94), p=0.001 0.82 (0.76-0.89), p<0.00001
Taxane given sequentially or concurrently with anthracycline
Concurrent 0.79 (0.66-0.94), p=0.007 0.79 (0.70-0.90), p=0.0003
Sequential 0.82 (0.75-0.90), p<0.0001 0.81 (0.76-0.88), p<0.00001
Addition or substitution of taxane
Addition 0.84 (0.76-0.93), p=0.0008 0.82 (0.76-0.89), pd0.00001
Substitution 0.76 (0.67-0.87), p<0.0001 0.78 (0.71-0.86), p<0.00001
Lymph node status
Node positive only 0.81 (0.74-0.89), p<0.00001 0.81 (0.76-0.87), p<0.00001
Node positive & negative 0.81 (0.69-0.95), p=0.01 0.80 (0.71-0.91), p=0.0004
Duration of chemotherapy
Longer duration 0.85 (0.77-0.94), p=0.002 0.83 (0.77-0.90), p<0.00001
Same duration 0.76 (0.67-0.86), p<0.0001 0.77 (0.70-0.85), p<0.00001

Notes: CI=confidence interval; OR=odds ratio; **All sub-group analyses were statistically significant

Table 3. Details of neoadjuvant trials
TRIAL PATIENT NUMBERS INTERVENTION COMPARATOR
NSABP B-2716 1605 AC x 4 D x 4 AC x 4
MDACC17 174 P x 4 FAC x 4 FAC x 4
Dieras18 200 AP x 4 T AC x 4 T
Learn19 144 AC x 4 T D x 4 AC x 4 T
Malamos20 35 PE x 3 FEC x 3
Lee21 78 DC x 4 AC x 4
ACCOG22 363 AD x 6 AC x 6
Aberdeen23 162 CVAPr x 4 D x 4 CVAPr x 4 CVAPr x 4

Notes: A=doxorubicin; C=cyclophosphamide; D=docetaxel; E=epirubicin; F=flurouracil; M=methotrexate; P=paclitaxel; T=trastuzumab; V=vinorelbine

Published using CeCC Docbook Manager